Awards made under Performance Share Plan

RNS Number : 4752B

e-Therapeutics plc

07 January 2015

 



e-Therapeutics plc ("e-Therapeutics" or the "Company")

Awards made under the e-Therapeutics Performance Share Plan 2013 (the "Performance Share Plan")

Oxford and Newcastle, UK 7 January 2015 - e-Therapeutics (AIM: ETX) announces that various awards were made to Directors and other employees on 6 January 2015 under the Performance Share Plan, as set out in the tables below.  All awards (which are either basic or supplementary awards) take the form of options to acquire, at par, ordinary shares of 0.1p each ("Shares"), with vesting subject to certain performance criteria. 

Vesting of all awards under the Performance Share Plan is based on the extent to which the average closing share price of a Share during the 20 dealing days ending on the third anniversary of the Grant Date (as set out below) or, in the event of an earlier change of control of the Company, the price offered by the party acquiring control of the Company (in each case the "Closing Price"), exceeds the average closing share price of a Share during the 20 dealing days prior to the Grant Date (the "Opening Price").  Vested awards may only be exercised on or after the earlier of (a) 6 January 2018 and (b) a change of control of the Company.

For basic awards, 25% of Shares the subject of awards will vest if the Closing Price exceeds the Opening Price by 25%, and vesting will increase pro-rata up to 100% of the award where the Closing Price exceeds the Opening Price by 100% or more.  For supplementary awards, vesting will occur only if the Closing Price exceeds the Opening Price by 150% or more.

The third table below indicates the relevant Market Prices.

Directors' Awards:

	Basic Award	Supplementary Award	Total No. of Options after this grant (as % of Issued Share Capital)	Total No. of Shares held (as % of Issued Share Capital)
Malcolm Young	594,827	594,827	2,857,036 (1.08%)	20,644,958 (7.81%)
Stephen Self	344,827	344,827	3,027,120* (1.15%)	273,577 (0.10%)
Steve Medlicott	258,620	258,620	1,562,694 (0.59%)	100,000 (0.04%)

* includes an interest in 154,428 options in issue held by Mr Self's wife, who is an employee of the Company.

Awards to Other Employees:

Basic Award	Supplementary Award
880,207	440,096

As at the date of this announcement, and following the above, there are outstanding options over 12,937,539 Shares, amounting to approximately 4.89% of the Company's current issued share capital. Since the last options grant on 8 July 2014, a total of 144,690 options have been exercised (announced on 5 August 2014) and a further 1,549,379 options have lapsed unvested.

Opening Prices and Market Prices for vesting against performance criteria:

Grant Date	Opening Price	Basic award		Supplementary award
		Closing Price exceeds Opening Price by 25%	Closing Price exceeds Opening Price by 100%	Closing Price exceeds Opening Price by 150%
6 January 2015	27.625p	34.53125p	55.25p	69.0625p

-Ends-

Contacts:

e-Therapeutics plc

Steve Medlicott, Finance Director

Tel: [phone]

www.etherapeutics.co.uk 

N+1 Singer

Aubrey Powell / Jen Boorer

Tel: [phone]

www.n1singer.com 

Instinctif Partners

Melanie Toyne-Sewell / Emma Barlow

Tel: [phone]

Email: [e-mail]

About e-Therapeutics plc

e-Therapeutics is an AIM-quoted drug discovery and development company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company's discovery and development activity is currently focused in cancer and disorders of the nervous system.

e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company, please visit www.etherapeutics.co.uk.

 

END

 

 

RDSUGUUGGUPAPGQ